ADA and infection: Concerning safety, VDZ did not increase the risk of infections compared with placebo (OR 1.03, 95% CI 0.60–1.79), while anti-TNFs were associated with more infections with statistical significance in the case of GOL (OR 1.85, 95% CI 1.20–2.86) but without it in the case of IFX (OR 1.30, 95% CI 0.60–179) and ADA (OR 1.23, 95% CI 0.91–1.65).